About Karyopharm

Contact Information:

Tracy Bonds
tbonds@karyopharm.com
(904) 535-2650

Virtual Exhibit Hall Home

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Additional Information
Learn About our New Indication
Product Website
Mechanism of Action
Prescribing Information
Patient Information
Patients Resources & Support
Twitter
LinkedIn